葛兰素史克-话题@MedSci

#葛兰素史克#

69篇内容 | 2643人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1315745, encodeId=b1501315e4573, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克收入下滑 CEO薪酬减半, objectType=article, longId=47600, objectId=90864e60094, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90864e60094, replyNumber=0, likeNumber=82, createdTime=2015-03-04, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90864e60094, moduleTitle=葛兰素史克收入下滑 CEO薪酬减半, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90864e60094)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315744, encodeId=410f1315e448f, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=Adimab宣布将与葛兰素史克公司合作开发双特异性抗体, objectType=article, longId=45520, objectId=fe4045520df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe4045520df, replyNumber=0, likeNumber=80, createdTime=2015-01-17, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe4045520df, moduleTitle=Adimab宣布将与葛兰素史克公司合作开发双特异性抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe4045520df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315743, encodeId=15bd1315e4342, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=诺华葛兰素史克$220亿资产置换交易或下月获欧盟批准, objectType=article, longId=43487, objectId=55bf4348ee4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55bf4348ee4, replyNumber=0, likeNumber=53, createdTime=2014-12-05, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55bf4348ee4, moduleTitle=诺华葛兰素史克$220亿资产置换交易或下月获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55bf4348ee4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315742, encodeId=14801315e42af, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克反贿风暴仍将继续被罚30亿只是坏日子开始, objectType=article, longId=40550, objectId=b8c04055073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8c04055073, replyNumber=0, likeNumber=61, createdTime=2014-09-24, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8c04055073, moduleTitle=葛兰素史克反贿风暴仍将继续被罚30亿只是坏日子开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8c04055073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315741, encodeId=caa81315e414e, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克生产的埃博拉病毒疫苗将在美国开始临床实验, objectType=article, longId=39743, objectId=edbf39e43fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edbf39e43fd, replyNumber=0, likeNumber=55, createdTime=2014-08-31, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edbf39e43fd, moduleTitle=葛兰素史克生产的埃博拉病毒疫苗将在美国开始临床实验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edbf39e43fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315740, encodeId=14961315e40f6, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克和辉瑞HIV三合一药物Triumeq获FDA批准, objectType=article, longId=39712, objectId=0daf39e120a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0daf39e120a, replyNumber=0, likeNumber=77, createdTime=2014-08-30, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0daf39e120a, moduleTitle=葛兰素史克和辉瑞HIV三合一药物Triumeq获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0daf39e120a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315739, encodeId=cb121315e39fe, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=FDA批准葛兰素史克Promacta新适应症, objectType=article, longId=39711, objectId=32dd39e1102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32dd39e1102, replyNumber=0, likeNumber=53, createdTime=2014-08-30, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32dd39e1102, moduleTitle=FDA批准葛兰素史克Promacta新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32dd39e1102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315738, encodeId=0b921315e38e5, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=一年连中四元——葛兰素史克哮喘新药Arnuity Ellipta获FDA批准, objectType=article, longId=39541, objectId=3d8239541b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d8239541b6, replyNumber=0, likeNumber=80, createdTime=2014-08-27, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d8239541b6, moduleTitle=一年连中四元——葛兰素史克哮喘新药Arnuity Ellipta获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d8239541b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315737, encodeId=ec371315e37eb, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克开发埃博拉病毒疫苗即将进入临床阶段, objectType=article, longId=39217, objectId=66243921e09, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66243921e09, replyNumber=0, likeNumber=76, createdTime=2014-08-20, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66243921e09, moduleTitle=葛兰素史克开发埃博拉病毒疫苗即将进入临床阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66243921e09)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315736, encodeId=86961315e364c, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=中国公布葛兰素史克行贿案调查结果, objectType=article, longId=34768, objectId=367f34e6845, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367f34e6845, replyNumber=0, likeNumber=85, createdTime=2014-05-17, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367f34e6845, moduleTitle=中国公布葛兰素史克行贿案调查结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=367f34e6845)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315735, encodeId=e4e31315e3505, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克在美国召回非处方减肥药Alli, objectType=article, longId=32522, objectId=202f3252217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=202f3252217, replyNumber=0, likeNumber=84, createdTime=2014-03-30, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=202f3252217, moduleTitle=葛兰素史克在美国召回非处方减肥药Alli, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=202f3252217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315734, encodeId=0a641315e347c, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克HIV新药Tivicay获欧盟批准, objectType=article, longId=29870, objectId=bdb3298e0cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdb3298e0cc, replyNumber=0, likeNumber=58, createdTime=2014-01-25, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdb3298e0cc, moduleTitle=葛兰素史克HIV新药Tivicay获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdb3298e0cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315733, encodeId=7a891315e33ef, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克HIV新药Tivicay获欧盟批准, objectType=article, longId=29815, objectId=9b282981528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b282981528, replyNumber=0, likeNumber=95, createdTime=2014-01-24, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b282981528, moduleTitle=葛兰素史克HIV新药Tivicay获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b282981528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315732, encodeId=d20f1315e321f, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克叫停回扣式售药停止向医生提供药品宣讲费, objectType=article, longId=28332, objectId=628328332a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=628328332a9, replyNumber=0, likeNumber=50, createdTime=2013-12-21, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=628328332a9, moduleTitle=葛兰素史克叫停回扣式售药停止向医生提供药品宣讲费, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=628328332a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315731, encodeId=b7f41315e31df, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克取消医药代表销售目标, objectType=article, longId=28237, objectId=edb12823e1c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edb12823e1c, replyNumber=0, likeNumber=65, createdTime=2013-12-20, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edb12823e1c, moduleTitle=葛兰素史克取消医药代表销售目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edb12823e1c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315730, encodeId=cb251315e3010, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克向FDA提交FF单药疗法新药申请, objectType=article, longId=25823, objectId=da872582317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da872582317, replyNumber=0, likeNumber=73, createdTime=2013-10-27, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da872582317, moduleTitle=葛兰素史克向FDA提交FF单药疗法新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da872582317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315729, encodeId=ad731315e291d, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克Revolade新适应症获欧盟批准, objectType=article, longId=25020, objectId=cd2925020ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2925020ce, replyNumber=0, likeNumber=65, createdTime=2013-09-28, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2925020ce, moduleTitle=葛兰素史克Revolade新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd2925020ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315728, encodeId=85191315e2836, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克vercirnonIII期试验失败, objectType=article, longId=23370, objectId=395b233e026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=395b233e026, replyNumber=0, likeNumber=67, createdTime=2013-08-28, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=395b233e026, moduleTitle=葛兰素史克vercirnonIII期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=395b233e026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315727, encodeId=207f1315e27dd, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克Tyberb新适应症获欧盟批准, objectType=article, longId=23132, objectId=a7b72313238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7b72313238, replyNumber=0, likeNumber=76, createdTime=2013-08-21, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7b72313238, moduleTitle=葛兰素史克Tyberb新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7b72313238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315726, encodeId=a0371315e26b9, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=FDA：葛兰素史克HIV新药Tivicay获FDA批准, objectType=article, longId=23001, objectId=974c2300133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=974c2300133, replyNumber=0, likeNumber=74, createdTime=2013-08-17, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=974c2300133, moduleTitle=FDA：葛兰素史克HIV新药Tivicay获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=974c2300133)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

葛兰素史克

2020-05-29

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克收入下滑 CEO薪酬减半

2015-03-04

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

Adimab宣布将与葛兰素史克公司合作开发双特异性抗体

2015-01-17

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

诺华葛兰素史克$220亿资产置换交易或下月获欧盟批准

2014-12-05

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克反贿风暴仍将继续被罚30亿只是坏日子开始

2014-09-24

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克生产的埃博拉病毒疫苗将在美国开始临床实验

2014-08-31

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克和辉瑞HIV三合一药物Triumeq获FDA批准

2014-08-30

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

FDA批准葛兰素史克Promacta新适应症

2014-08-30

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

一年连中四元——葛兰素史克哮喘新药Arnuity Ellipta获FDA批准

2014-08-27

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克开发埃博拉病毒疫苗即将进入临床阶段

2014-08-20

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

中国公布葛兰素史克行贿案调查结果

2014-05-17

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克在美国召回非处方减肥药Alli

2014-03-30

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克HIV新药Tivicay获欧盟批准

2014-01-25

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克HIV新药Tivicay获欧盟批准

2014-01-24

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克叫停回扣式售药停止向医生提供药品宣讲费

2013-12-21

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克取消医药代表销售目标

2013-12-20

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克向FDA提交FF单药疗法新药申请

2013-10-27

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克Revolade新适应症获欧盟批准

2013-09-28

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克vercirnonIII期试验失败

2013-08-28

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克Tyberb新适应症获欧盟批准

2013-08-21

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

FDA：葛兰素史克HIV新药Tivicay获FDA批准

2013-08-17

科室
- - 订阅+
  - 更多科室
工具
服务